Fresenius Medical Care Adjusts China Commercial Strategy To Support Long-Term Growth And Strengthen Market Position Through More Localized Portfolio, Increased Commercialization Of Local Innovation And Focused Go-To-Market Plans

Fresenius Medical Care is adjusting its commercial strategy in China, which accounts for approximately 6-7% of its Care Enablement segment revenues, to enhance long-term growth and market position. The company has appointed Rex Liu as the new General Manager and will focus on innovative dialysis technologies while discontinuing the 4008A hemodialysis system and exiting the peritoneal dialysis business, resulting in one-time costs of about €110 million. Despite these changes, the company does not anticipate a significant impact on future revenue from its China operations.